September 2025 Danaher expanded its molecular diagnostic solutions through advancements in PCR technologies, automation, and infectious disease testing platforms. The company focused on improving laboratory workflows and expanding diagnostic capabilities.
July 2025 bioMérieux expanded its molecular diagnostics capabilities by advancing syndromic testing platforms and pathogen identification solutions. The developments focused on enabling faster diagnosis and improving infectious disease management.
June 2025 Abbott expanded its molecular diagnostics portfolio by enhancing infectious disease testing technologies, including rapid molecular platforms and point-of-care solutions. The company focused on improving diagnostic accessibility, accuracy, and speed.
May 2025 Roche Diagnostics expanded its infectious disease molecular diagnostics portfolio by advancing PCR-based testing platforms and automated molecular diagnostic solutions. The developments focused on improving rapid pathogen detection, laboratory efficiency, and clinical decision-making.